Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that the United States Food and Drug Administration (FDA) has granted an orphan drug designation for the use of the patented adult stem cell technology in patients undergoing bone marrow transplantation.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced that a full licence agreement has been signed with SSL International plc (LSE:SSL) in relation to the VivaGel(R) coated condom. SSL manufactures and sells Durex(R) condoms, the market-leading condom brand worldwide.
Polartechnics Limited (ASX:PLT)(PINK:PLTFF) today announced it had reached a strategic agreement with its preferred business partners, Genera Biosystems and Healthscope, for the commercialisation of CerviScreen, which is a new device to identify sexually transmitted Human Papillomavirus (HPV) using self-sampled specimens.
Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced that the Company has been informed that an additional US$5.5 million in funding will be made available by the US Army for the Company's planned Phase II clinical trial of NNZ-2566 in traumatic brain injury (TBI). With the previously announced grant of US$4 million to cover direct costs of the study, this results in a total commitment of approximately US$10 million.
Mesoblast Limited's (ASX:MSB)(OTC:MBLTY) product has statistically significant higher fusion rates in anterior cervical interbody operations compared to a competitor. We believe the competitor's FY08 cervical fusion sales were cA$325m, but has recently been forced to exit the market.
The regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced its financial results for the year ending 30 June 2008. Mesoblast is well positioned with sufficient cash reserves for its ongoing clinical trial activities and near-term strategic objectives.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced its full year financial results for the year ended 30 June 2008.
